{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:42:20Z","timestamp":1793814140058,"version":"4.6.1"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Plasma phospho-tau 217 (pTau217) is a biomarker for Alzheimer\u2019s disease (AD) pathology, reflecting amyloid (A\u03b2) and tau burden, but its role in Parkinson disease (PD) and 4-repeat(4R)-tauopathies remains incompletely understood. We measured plasma pTau217 across the cognitive spectrum of Lewy body diseases (PD, Dementia with Lewy bodies [DLB]) and in 4R-tauopathies, comparing these groups to cognitively unimpaired (CU) and mild cognitive impairment (MCI) individuals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Participants included 18 cognitively normal PD (PD-NC), 32 PD with MCI, and 7 PD with dementia (PDD), alongside 4 DLB patients, grouped as PDD\/DLB. The 4R-tauopathy group included 28 Progressive Supranuclear Palsy (PSP) and 4 corticobasal syndrome (CBS) patients, compared to 51 CU and 26 MCI individuals. Ptau217 was measured using the fully automated Lumipulse platform, with values adjusted for creatinine levels. Further, the presence of AD-pathology was defined using a validated cut-off based on A\u03b2-PET.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      PTau217 levels were significantly lower in PD-NC and CU individuals compared to those with greater cognitive impairment (PD-MCI, PDD\/DLB, and PSP\/CBS), and MCI individuals. AD co-pathology was identified in 28% of PDD\/DLB and PSP\/CBS patients, 16% of PD-MCI, and none of PD-NC. MCI showed the highest pTau217 positivity (35%), while 8% of CU individuals were positive despite normal cognition. In PD, pTau217 negatively correlated with cognitive performance, as assessed by Montreal Cognitive Assessment (MoCA:\n                      <jats:italic>rs<\/jats:italic>\n                      \u202f=\u202f\u22120.38,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.004) and Mini-Mental State Examination (MMSE:\n                      <jats:italic>rs<\/jats:italic>\n                      \u202f=\u202f\u22120.37,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.006).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Plasma pTau217 levels serve as a scalable, non-invasive marker of AD-pathology across Lewy body diseases, PSP\/CBS, and MCI\/CU populations. AD co-pathology independently contributes to cognitive deficits in PD, but not in PSP\/CBS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2025.1638852","type":"journal-article","created":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T11:56:40Z","timestamp":1755259000000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Detecting amyloid and tau pathology in Parkinson\u2019s disease, 4R-tauopathies and control subjects with plasma pTau217"],"prefix":"10.3389","volume":"16","author":[{"given":"Giulia","family":"Musso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Fiorenzato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Misenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Cauzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Biundo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmelo A.","family":"Fogliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Bonato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wassilios G.","family":"Meissner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Campagnolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miryam","family":"Carecchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Vianello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Guerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Cosma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annachiara","family":"Cagnin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Cecchin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Montagnana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Antonini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,15]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"107255","DOI":"10.1016\/j.parkreldis.2024.107255","article-title":"The effect of amyloid and tau co-pathology on disease progression in Lewy body dementia: a systematic review","volume":"131","author":"Tan","year":"2025","journal-title":"Parkinsonism Relat Disord"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1002\/mds.26191","article-title":"Amyloid deposition in Parkinson\u2019s disease and cognitive impairment: a systematic review","volume":"30","author":"Petrou","year":"2015","journal-title":"Mov Disord"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1136\/jnnp-2019-321111","article-title":"Neuropathology of dementia in patients with Parkinson\u2019s disease: a systematic review of autopsy studies","volume":"90","author":"Smith","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s association workgroup","volume":"20","author":"Jack","year":"2024","journal-title":"Alzheimers Dement"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1002\/mds.28370","article-title":"Plasma Phospho-tau identifies Alzheimer\u2019s co-pathology in patients with Lewy body disease","volume":"36","author":"Hall","year":"2021","journal-title":"Mov Disord"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"e087594","DOI":"10.1002\/alz.087594","article-title":"The effect of AD co-pathology on cognitive phenotype and FDG-PET patterns in Parkinson\u2019s disease with cognitive impairment","volume":"20","author":"Castro-Labrador","year":"2024","journal-title":"Alzheimers Dement"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1001\/jamaneurol.2022.4485","article-title":"Association of Phosphorylated tau Biomarkers with Amyloid Positron Emission Tomography vs tau positron emission tomography","volume":"80","author":"Therriault","year":"2023","journal-title":"JAMA Neurol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"105405","DOI":"10.1016\/j.ebiom.2024.105405","article-title":"Detection and staging of Alzheimer\u2019s disease by plasma pTau217 on a high throughput immunoassay platform","volume":"109","author":"Feizpour","year":"2024","journal-title":"EBioMedicine"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"e11170","DOI":"10.15252\/emmm.201911170","article-title":"Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer\u2019s disease","volume":"11","author":"Palmqvist","year":"2019","journal-title":"EMBO Mol Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.jalz.2018.02.013","article-title":"Plasma phospho-tau 181 increases with Alzheimer\u2019s disease clinical severity and is associated with tau- and amyloid-positron emission tomography","volume":"14","author":"Mielke","year":"2018","journal-title":"Alzheimers Dement"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1038\/s41591-024-02869-z","article-title":"Highly accurate blood test for Alzheimer\u2019s disease is similar or superior to clinical cerebrospinal fluid tests","volume":"30","author":"Barth\u00e9lemy","year":"2024","journal-title":"Nat Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"e14022","DOI":"10.15252\/emmm.202114022","article-title":"Soluble P-tau 217 reflects amyloid and tau pathology and mediates the association of amyloid with tau","volume":"13","author":"Mattsson-Carlgren","year":"2021","journal-title":"EMBO Mol Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/s43587-023-00471-5","article-title":"A two-step workflow based on plasma p-tau 217 to screen for amyloid \u03b2 positivity with further confirmatory testing only in uncertain cases","volume":"3","author":"Brum","year":"2023","journal-title":"Nat Aging"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/ane.13700","article-title":"Blood based biomarkers for movement disorders","volume":"146","author":"Morris","year":"2022","journal-title":"Acta Neurol Scand"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"e70274","DOI":"10.1002\/alz.70274","article-title":"Neuroimaging and plasma biomarker differences and commonalities in Lewy body dementia subtypes","volume":"21","author":"Hannaway","year":"2025","journal-title":"Alzheimers Dement"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1001\/jamaneurol.2023.0488","article-title":"Evaluation of plasma phosphorylated tau 217 for differentiation between Alzheimer disease and frontotemporal lobar degeneration subtypes among patients with Corticobasal syndrome","volume":"80","author":"Vande Vrede","year":"2023","journal-title":"JAMA Neurol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"e113","DOI":"10.1515\/cclm-2024-1091","article-title":"Diagnostic performances and cut-off verification of blood pTau 217 on the Lumipulse platform for amyloid deposition in Alzheimer\u2019s disease","volume":"63","author":"Musso","year":"2025","journal-title":"Clin Chem Lab Med"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson\u2019s disease","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov Disord"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","article-title":"Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB consortium","volume":"89","author":"McKeith","year":"2017","journal-title":"Neurology"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1212\/CON.0000000000000309","article-title":"Lewy body dementias: dementia with Lewy bodies and Parkinson disease dementia","volume":"22","author":"Gomperts","year":"2016","journal-title":"Contin Lifelong Learn Neurol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s00702-017-1821-9","article-title":"Dementia with Lewy bodies and Parkinson\u2019s disease-dementia: current concepts and controversies","volume":"125","author":"Jellinger","year":"2018","journal-title":"J Neural Transm"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/mds.26987","article-title":"Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria","volume":"32","author":"Hoglinger","year":"2017","journal-title":"Mov Disord"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1212\/WNL.0b013e31827f0fd1","article-title":"Criteria for the diagnosis of corticobasal degeneration","volume":"80","author":"Armstrong","year":"2013","journal-title":"Neurology"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1093\/ageing\/afaa228","article-title":"Mild cognitive impairment: the Manchester consensus","volume":"50","author":"Dunne","year":"2021","journal-title":"Age Ageing"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"123283","DOI":"10.1016\/j.jns.2024.123283","article-title":"Optimal MMSE and MoCA cutoffs for cognitive diagnoses in Parkinson\u2019s disease: a data-driven decision tree model","volume":"466","author":"Fiorenzato","year":"2024","journal-title":"J Neurol Sci"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"921062","DOI":"10.3389\/fpsyg.2022.921062","article-title":"MASCoD-multidimensional assessment of subjective cognitive decline","volume":"13","author":"Maffoni","year":"2022","journal-title":"Front Psychol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/mds.24893","article-title":"Diagnostic criteria for mild cognitive impairment in Parkinson\u2019s disease: Movement Disorder Society task force guidelines","volume":"27","author":"Litvan","year":"2012","journal-title":"Mov Disord"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1002\/mds.29678","article-title":"Brain dynamics complexity as a signature of cognitive decline in Parkinson\u2019s disease","volume":"39","author":"Fiorenzato","year":"2024","journal-title":"Mov Disord"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"120014","DOI":"10.1016\/j.cca.2024.120014","article-title":"Blood biomarkers for Alzheimer\u2019s disease with the Lumipulse automated platform: age-effect and clinical value interpretation","volume":"565","author":"Musso","year":"2025","journal-title":"Clin Chim Acta"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1515\/cclm-2022-0770","article-title":"Pre-analytical variability of the Lumipulse immunoassay for plasma biomarkers of Alzheimer\u2019s disease","volume":"61","author":"Musso","year":"2023","journal-title":"Clin Chem Lab Med"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"e210287","DOI":"10.1212\/WNL.0000000000210287","article-title":"Quantitative assessment of the effect of chronic kidney disease on plasma P-tau 217 concentrations","volume":"104","author":"Bornhorst","year":"2025","journal-title":"Neurology"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1038\/s41591-022-01822-2","article-title":"Performance of plasma phosphorylated tau 181 and 217 in the community","volume":"28","author":"Mielke","year":"2022","journal-title":"Nat Med"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/s41598-024-51334-x","article-title":"Clinical evaluation of a novel plasma pTau217 electrochemiluminescence immunoassay in Alzheimer\u2019s disease","volume":"14","author":"Kivis\u00e4kk","year":"2024","journal-title":"Sci Rep"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"760518","DOI":"10.3389\/fneur.2021.760518","article-title":"Quantification of brain \u03b2-amyloid load in Parkinson\u2019s disease with mild cognitive impairment: a PET\/MRI study","volume":"12","author":"Garon","year":"2021","journal-title":"Front Neurol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"fcab180","DOI":"10.1093\/braincomms\/fcab180","article-title":"The contribution of beta-amyloid to dementia in Lewy body diseases: a 1-year follow-up study","volume":"3","author":"Biundo","year":"2021","journal-title":"Brain Commun"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3233\/JAD-180390","article-title":"Brain amyloid contribution to cognitive dysfunction in early-Stage Parkinson\u2019s disease: the PPMI dataset","volume":"66","author":"Fiorenzato","year":"2018","journal-title":"J Alzheimer\u2019s Dis"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"828","DOI":"10.14283\/jpad.2023.83","article-title":"Two-year prognostic utility of plasma p 217+tau across the Alzheimer\u2019s continuum","volume":"10","author":"Feizpour","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"e14458","DOI":"10.1002\/alz.14458","article-title":"Diagnostic accuracy of phosphorylated tau 217 in detecting Alzheimer\u2019s disease pathology among cognitively impaired and unimpaired: a systematic review and meta-analysis","volume":"21","author":"Khalafi","year":"2025","journal-title":"Alzheimers Dement"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1007\/s00415-025-12996-3","article-title":"Blood phosphorylated tau 217 distinguishes amyloid-positive from amyloid-negative subjects in the Alzheimer\u2019s disease continuum. A systematic review and meta-analysis","volume":"272","author":"Antonioni","year":"2025","journal-title":"J Neurol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1093\/brain\/awae372","article-title":"Patterns of tau, amyloid and synuclein pathology in ageing, Alzheimer\u2019s disease and synucleinopathies","volume":"148","author":"Colloby","year":"2024","journal-title":"Brain"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1007\/s00702-016-1589-3","article-title":"Montreal cognitive assessment (MoCA) and mini-mental state examination (MMSE) performance in progressive supranuclear palsy and multiple system atrophy","volume":"123","author":"Fiorenzato","year":"2016","journal-title":"J Neural Transm"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1002\/mds.27198","article-title":"Cognitive impairment in progressive supranuclear palsy is associated with tau burden","volume":"32","author":"Koga","year":"2017","journal-title":"Mov Disord"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.parkreldis.2017.12.016","article-title":"Pittsburgh compound B and AV-1451 positron emission tomography assessment of molecular pathologies of Alzheimer\u2019s disease in progressive supranuclear palsy","volume":"48","author":"Whitwell","year":"2018","journal-title":"Parkinsonism Relat Disord"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"3234","DOI":"10.1093\/brain\/awaa286","article-title":"Longitudinal plasma p-tau 217 is increased in early stages of Alzheimer\u2019s disease","volume":"143","author":"Mattsson-Carlgren","year":"2020","journal-title":"Brain"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1136\/jnnp-2025-335830","article-title":"Tailoring thresholds for interpreting plasma p-tau 217 levels","volume":"96","author":"Ahn","year":"2025","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/s13195-024-01630-5","article-title":"Analytical and clinical performance of eight Simoa\u00ae and Lumipulse\u00ae assays for automated measurement of plasma p-tau 181 and p-tau 217","volume":"16","author":"Wojda\u0142a","year":"2024","journal-title":"Alzheimer\u2019s Res Ther"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12987-025-00620-5","article-title":"Exploring the ability of plasma pTau217, pTau181 and beta-amyloid in mirroring cerebrospinal fluid biomarker profile of mild cognitive impairment by the fully automated Lumipulse\u00ae platform","volume":"22","author":"Catania","year":"2025","journal-title":"Fluids Barriers CNS"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"6739","DOI":"10.1007\/s00415-024-12631-7","article-title":"Diagnostic accuracy of automated Lumipulse plasma pTau-217 in Alzheimer\u2019s disease: a real-world study","volume":"271","author":"Cecchetti","year":"2024","journal-title":"J Neurol"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1638852\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T11:56:41Z","timestamp":1755259001000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1638852\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,15]]},"references-count":48,"alternative-id":["10.3389\/fneur.2025.1638852"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2025.1638852","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,15]]},"article-number":"1638852"}}